Neoadjuvant or Perioperative Approach in Lung Cancer

Numerous treatment options are currently available to reduce the risk of recurrence in patients with early-stage resectable non–small-cell lung cancer (NSCLC). These approaches include neoadjuvant and adjuvant therapy, which have been shown to improve outcomes in patients undergoing surgery. Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) may further improve clinical outcomes. Two previous trials of adjuvant therapy have shown the benefit of immunotherapy after surgical resection. In the IMpower010 trial,1 atezolizumab had a disease-free survival benefit after adjuvant chemotherapy in patients with resected stage II to IIIA NSCLC, with more benefit in the subgroup of patients . . .